# Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma

Source: https://onco.cc/trials/nct07282587/  
OnCo record `nct07282587` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of ONC206 in pheochromocytoma and paraganglioma, run by Jazz Pharmaceuticals, now recruiting.

## Summary

Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma is a phase 2 interventional study registered as NCT07282587 by Jazz Pharmaceuticals, with 90 participants planned, started 2026-01-02 and due to reach its primary completion in 2028-12-15. Interventions recorded: ONC206, ONC206: Dose 1 and ONC206: Dose 2.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07282587
- Phase: 2
- Setting: A Phase 2 Study of ONC206 in Advanced Pheochromocytoma and Paraganglioma
- Sponsor: Jazz Pharmaceuticals
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT07282587: https://clinicaltrials.gov/study/NCT07282587

## Connected records

- cancers: [Pheochromocytoma and paraganglioma (PPGL)](https://onco.cc/cancers/pheochromocytoma-paraganglioma/)
- companies: [Jazz Pharmaceuticals](https://onco.cc/companies/jazz/)

---
JSON: https://onco.cc/api/v1/entities/nct07282587.json